Compare Novo Nordisk A/S (NVO) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares Semiconductor ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while iShares Semiconductor ETF trades at $559.4 (market cap $48.19B). The key difference: Novo Nordisk A/S is far larger — about 3.4× iShares Semiconductor ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and iShares Semiconductor ETF for 46 Days on average.
| NVO | SOXX | |
|---|---|---|
Market Cap | $165.31B | $48.19B |
Volume | 11,432,838 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $655.01 |
52-Week Low | $35.29 | $268.10 |
Typical Hold Time | 116 Days | 46 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
SOXX trades at $563.28, down 3.37% on the day, with bullish technical signals from moving averages and a neutral oscillator reading. The ETF faces mixed sentiment with positive AI-driven earnings momentum countered by valuation concerns and Michael Burry's expanded short positions. Recent news highlights strong September performance driven by chip stock gains and AI infrastructure demand projections.
The semiconductor ETF's outlook hinges on sustained AI demand growth versus elevated valuations. BofA projects the global chip market to nearly double by 2030, providing fundamental support, but concentration risk and potential multiple compression present headwinds. Earnings growth remains the key catalyst for further upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
